The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 336:1131-1141 April 17, 1997 Number 16
NextNext

Apoptosis in the Failing Human Heart
Giorgio Olivetti, M.D., Rakesh Abbi, M.D., Federico Quaini, M.D., Jan Kajstura, Ph.D., Wei Cheng, M.D., James A. Nitahara, M.D., Eugenio Quaini, M.D., Carla Di Loreto, M.D., Carlo A. Beltrami, M.D., Stanislaw Krajewski, M.D., Ph.D., John C. Reed, M.D., Ph.D., and Piero Anversa, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Loss of myocytes is an important mechanism in the development of cardiac failure of either ischemic or nonischemic origin. However, whether programmed cell death (apoptosis) is implicated in the terminal stages of heart failure is not known. We therefore studied the magnitude of myocyte apoptosis in patients with intractable congestive heart failure.

Methods Myocardial samples were obtained from the hearts of 36 patients who underwent cardiac transplantation and from the hearts of 3 patients who died soon after myocardial infarction. Samples from 11 normal hearts were used as controls. Apoptosis was evaluated histochemically, biochemically, and by a combination of histochemical analysis and confocal microscopy. The expression of two proto-oncogenes that influence apoptosis, BCL2 and BAX, was also determined.

Results Heart failure was characterized morphologically by a 232-fold increase in myocyte apoptosis and biochemically by DNA laddering (an indicator of apoptosis). The histochemical demonstration of DNA-strand breaks in myocyte nuclei was coupled with the documentation of chromatin condensation and fragmentation by confocal microscopy. All these findings reflect apoptosis of myocytes. The percentage of myocytes labeled with BCL2 (which protects cells against apoptosis) was 1.8 times as high in the hearts of patients with cardiac failure as in the normal hearts, whereas labeling with BAX (which promotes apoptosis) remained constant. The near doubling of the expression of BCL2 in the cardiac tissue of patients with heart failure was confirmed by Western blotting.

Conclusions Programmed death of myocytes occurs in the decompensated human heart in spite of the enhanced expression of BCL2; this phenomenon may contribute to the progression of cardiac dysfunction.


Source Information

From the Departments of Medicine (G.O., J.K., W.C., J.A.N., P.A.) and Pathology (R.A.), New York Medical College, Valhalla; the Department of Pathology, University of Parma, Parma, Italy (F.Q.); the Department of Pathology, University of Udine, Udine, Italy (C.D., C.A.B.); the De Gasperis Division of Cardiac Surgery, Milan, Italy (E.Q.); and the Burnham Institute, La Jolla, Calif. (S.K., J.C.R.).

Address reprint requests to Dr. Anversa at the Department of Medicine, Vosburgh Pavilion 302, New York Medical College, Valhalla, NY 10595.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.